explore -WSS

explore

author：fashion 2025-09-29 01:38:14 - browse：1543

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Data show record exodus of life scientists from academia

focus

WSS

FDA advisers vote against ALS treatment from BrainStorm

7 of the most gruesome medical devices in history

Intercept Pharmaceuticals sells itself for less than $1 billion

Senator probes 340B programs at Cleveland Clinic, Bon Secours

FDA official pushes for dedicated emerging pathogens team

How one patient went off dialysis — and others can too

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

Elizabeth Warren probes abortion access

Virginia high school admissions case could be legal follow

After a drawn out lobbying fight, ARPA

DIEP, the 'gold standard' of breast reconstruction, is under threat

Covid vaccines: Private market messier than government rollout

DIEP, the 'gold standard' of breast reconstruction, is under threat

7 of the most gruesome medical devices in history

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Listen: Who gets the credit for GLP

entertainment

Why an extreme heat and wildfire smoke combination can be so dangerous

Ionis has late

Paxlovid should be available without a positive Covid test

AbbVie dramatically boosts its spending on lobbying

WHO recommends dropping component of many flu vaccines

Researchers use wearables data and AI to predict preterm birth risk

entertainment

focus

focus

focus